A phase II study of 9 nitrocamptothecin [rubitecan] for hormone-refractory prostate cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rubitecan (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 13 Jul 2016 Biomarkers information updated
- 11 Jan 2007 Status change
- 28 Sep 2005 New trial record.